PharmaShots | Incisive News in 3 Shots

Subscribe Now

Tibsovo

Servier’s Tibsovo (ivosidenib) Receives the US FDA's Approval for the Treatment of IDH1-mutated Acute Myeloid Leukemia

Servier’s Tibsovo (ivosidenib) Receives the US FDA's Approval for the Treatment of IDH1-mutated Acute Myeloid Leukemia

May 26, 2022

Servier Publishes Results of Tibsovo (ivosidenib) in P-III (AGILE) Trial for IDH1-Mutated Acute Myeloid Leukemia in NEJM

Servier Publishes Results of Tibsovo (ivosidenib) in P-III (AGILE) Trial for IDH1-Mutated Acute Myeloid Leukemia in NEJM

April 21, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us